The population identified in the clinical environment is women, and the morbidity affecting them is Pulmonary Arterial Hypertension (PAH). According to Talwar et al. (2017), Pulmonary hypertension (PH) refers to a group of diseases characterized by abnormally elevated pulmonary pressures caused by various chronic conditions. The disease is known to have nonspecific symptoms leading to delays in evaluation and diagnosis. However, some of the symptoms include increased shortness of breath on exertion, palpitations, and fatigue, making it difficult to differentiate these symptoms from other cardiopulmonary diseases (Verma, Sahni, Vijayan, & Talwar, 2016). From various forms of PH morbidity, pulmonary arterial hypertension (PAH) stands out as a rare disease that affects mostly women, with an estimated median survival of 2.8 years without treatment. One of the health behaviors associated with Pulmonary Arterial hypertension is depression. According to Verma, Sahni, Vijayan, & Talwar (2016), once a PAH diagnosis is verified, patients have to start deal with mixed emotions of comprehending and consenting the reality in conjunction with adjustment to their condition. The complex nature of PAH is the uncertain future and lack of a cure, impelling feelings of being overwhelmed in a patient. Consequently, patients report restrictions in their ability to perform daily tasks such as working, traveling, shopping, and household chores.
Growing older can increase your risk of developing pulmonary hypertension. The condition is more often diagnosed in people ages thirty to sixty. Other factors include a family history of the condition, being overweight, a blood-clotting disorder, genetics disorders, among many. One of the health promotion service utilized in treating PAH patients is Anticoagulation. According to Khan (2018), a meta-analysis demonstrated that the use of Anticoagulation might improve survival in idiopathic PAH patients while increasing mortality when used in scleroderma-associated-PAH patients.
Khan, S., M., Usman, S., M., Siddiqi, J., T., Khan, U., S., Murad, M., H., Mookadam, F., Figueredo, M., V., Krasuski, A., R., Benza, L., R., and Rich, J., D. (2018). Circulation: Cardiovascular Quality and Outcomes. Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension? American Heart Association Journal. 11(9). Retrieved 17 November 2020, from https://www.ahajournals.org/doi/epub/10.1161/CIRCOUTCOMES.118.004757
Talwar, A., Garcia, J., Tsai, H., Moreno, M., Lahm, T., Zamanian, R. T., Machado, R., Kawut, S. M., Selej, M., Mathai, S., D’Anna, L. H., Sahni, S., Rodriquez, E. J., Channick, R., Fagan, K., Gray, M., Armstrong, J., Rodriguez Lopez, J., de Jesus Perez, V., & Pulmonary Circulation Assembly. (2017). Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. American journal of respiratory and critical care medicine, 196(8), 32–47. Retrieved 17 November 2020, from https://doi.org/10.1164/rccm.201709-1821ST
Verma, S., Sahni, S., Vijayan, V. K., & Talwar, A. (2016). Depression in pulmonary arterial hypertension: An undertreated comorbidity. Lung India: official organ of Indian Chest Society, 33(1), 58–63. Retrieved 17 November 2020, from https://doi.org/10.4103/0970-2113.173072